Mesenchymal Stem Cell Therapy Market Size, Trends and Insights By Type (Autologous, Allogeneic), By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues), By Application (Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Mesoblast Limited
- TiGenix
- Osiris Therapeutics
- Celgene Corporation
- Vericel Corporation
- Athersys Inc.
- Others
Reports Description
Global Mesenchymal Stem Cell Therapy Market was valued at USD 3.4 Billion in 2024 and is expected to reach USD 7.7 Billion by 2033, at a CAGR of 12.7% during the forecast period 2024 – 2033.
Mesenchymal stem cell (MSC) treatment is a kind of regenerative medicine that uses mesenchymal stem cells generated from a variety of sources, including bone marrow, adipose tissue (fat), and umbilical cord tissue. Mesenchymal stem cells are multipotent cells that can differentiate into a variety of cell types, such as bone, cartilage, and fat.
Mesenchymal Stem Cell Therapy Market: Growth Factors
Increase in prevalence of chronic diseases
The growth in chronic illnesses has been a major driver of the mesenchymal stem cell (MSC) treatment industry. Chronic illnesses, such as cardiovascular problems, diabetes, autoimmune diseases, and orthopaedic ailments, provide considerable difficulties to global healthcare systems. MSCs have distinct regenerative and immunomodulatory capabilities, making them potential candidates for treating a variety of chronic diseases.
Their potential to differentiate into diverse cell types and promote tissue repair and regeneration has sparked renewed interest in MSC-based therapeutics. MSCs have also shown efficacy in modifying inflammatory responses and regulating immunological function, suggesting prospective therapy options for autoimmune illnesses and inflammatory ailments.
As the worldwide burden of chronic illnesses continues to expand, the need for new therapeutics such as MSCs is predicted to increase, driving development in the MSC therapy market. According to the US Centres for Disease Control and Prevention, 35.66% (33.36-36.04) of adults aged 50 and above would have at least one chronic illness by 2035, with the figure anticipated to rise to 47.81% (46.09-49.71) by 2050.
Growing prominence of regenerative medicine
The rising popularity of regenerative medicine is driving the mesenchymal stem cell treatment industry forward. Mesenchymal stem cells (MSCs) have great potential in regenerative medicine owing to their unique traits, such as their capacity to develop into diverse cell types and their immunomodulatory activities.
As regenerative medicine gains popularity as a viable method for treating a wide range of illnesses and injuries, demand for MSC-based treatments grows. MSCs are being investigated for their possible use in tissue regeneration, immunotherapy, and the treatment of degenerative ailments such as cartilage degeneration, heart disease, and neurological problems.
In addition, advances in cell culture techniques, genetic manipulation, and clinical research are driving innovation in MSC therapy, further supporting market expansion as more patients seek alternative viable treatment choices for challenging medical conditions. The Wake Forest Institute for Regenerative Medicine, a division of Wake Forest University School of Medicine, has been chosen to lead the Armed Forces Institute of Regenerative Medicine (AFIRM) Consortium.
The initiative, a USD 40 million, five-year contract from the Defence Health Agency (DHA), will focus on advancing regenerative medicine treatments for wartime injuries to the next level, eventually reaching the general population.
Mesenchymal Stem Cell Therapy Market: Restraints
High cost of treatment
The high treatment costs are a key obstacle to the expansion of the mesenchymal stem cell therapy industry. Stem cell treatments, notably those using mesenchymal stem cells (MSCs), may need sophisticated and expensive processes such as cell collection, growth, differentiation, and delivery.
Furthermore, the necessity for specialised equipment, competent workers, and tight regulatory standards adds to the high total cost of treatment. As an outcome, many patients may have restricted access to mesenchymal stem cell therapies, particularly those who lack sufficient financial means or insurance coverage.
Furthermore, the high cost of therapy may discourage healthcare practitioners from giving these therapies or incorporating them into routine clinical practice, limiting MSC therapies’ general adoption and financial success in the healthcare sector.
Initiatives to lower treatment costs through technical improvements, process optimisation, and regulatory streamlining are critical for overcoming this issue and increasing the cost and availability of mesenchymal stem cell therapy.
Mesenchymal Stem Cell Therapy Market: Opportunities
Advancement in tissue engineering
Advances in tissue engineering are driving the mesenchymal stem cell (MSC) treatment industry. Tissue engineering techniques enable the production of biomimetic settings that closely resemble the natural tissue milieu, hence improving MSC survival, multiplication and transformation.
These improvements allow for the creation of novel MSC-based therapeutics for a variety of medical illnesses, including orthopaedic injuries, cardiovascular ailments, autoimmune disorders, and neurological disorders. Furthermore, tissue engineering technologies enable the regulated distribution of MSCs to specific tissues or organs, hence increasing the effectiveness and accuracy of cell-based treatments.
Furthermore, the combination of tissue engineering and regenerative medicine methodologies promotes the development of next-generation MSC products with improved therapeutic capabilities, which drives growth and investment in the MSC treatment market. Recently, research on cellular reprogramming to cause adult stem cells to behave like pluripotent stem cells has been conducted.
The use of such cells would eliminate the problem of obtaining stem cells because they may be extracted from the patient’s bone marrow, blood, or adipose tissue.
Mesenchymal Stem Cell Therapy Market: Segmentation Analysis
The Global Mesenchymal Stem Cell Therapy market is segmented by type, source of insolation, application, and region. Based on type, the market is classified into autologous and allogeneic. Allogeneic dominated the market in 2023 with a market share of 58.7% and is expected to keep its dominance during the forecast period 2024-2033.
Allogeneic-driven mesenchymal stem cell treatment has grown in popularity due to its ability to treat a wide range of medical diseases. Allogeneic treatment avoids the need for individualised harvesting operations by using donor stem cells rather than the patient’s tissue, lowering costs and logistical issues.
Furthermore, allogeneic MSCs have a greater availability and scalability, making them more suitable for extensive clinical usage. This strategy also avoids any limits caused by the grade and density of a patient’s stem cells.
Moreover, allogeneic therapy opens up possibilities to standard medications, allowing for faster and more efficient delivery to patients. These aspects lead to the increasing interest and acceptance of allogeneic-driven mesenchymal stem cell treatment, pushing its importance in the market and providing potential opportunities for advancing regenerative medicine.
Based on the source of insolation, the market is classified into bone marrow, cord blood, peripheral blood, fallopian tube, fetal liver, lung and adipose tissues. Bone Marrow dominated the market in 2023 with a market share of 24.5% and is expected to keep its dominance during the forecast period 2024-2033.
The bone marrow drive for the mesenchymal stem cell (MSC) therapy market is fuelled by the vast reservoir of MSCs present inside bone marrow, making it a prominent source for extracting these versatile cells. As researchers probe more into the therapeutic potential of MSCs, bone marrow emerges as a key contribution to the growth of this sector.
The accessibility of bone marrow-derived MSCs, along with their potential to differentiate into diverse cell types and their immune-modulating capabilities, positions them as useful tools in the field of regenerative medicine. Furthermore, developments in isolation methods and the introduction of standardized procedures for MSC extraction from bone marrow further enhance their economic viability.
Consequently, pharmaceutical corporations, biotechnology businesses, and research institutes are increasingly investing in bone marrow-derived MSC research and development, pushing the growth of the MSC therapy market and fostering innovative treatments for a wide range of medical conditions.
Based on application, the market is classified into disease modelling, drug development & discovery, stem cell banking, tissue engineering, toxicology studies and others. Disease Modelling dominated the market in 2023 with a market share of 35.1% and is expected to keep its dominance during the forecast period 2024-2033.
Disease modelling is critical to driving the mesenchymal stem cell (MSC) treatment business forward. Researchers may use sophisticated computational and experimental models to mimic and investigate diverse illnesses, gaining insights into their underlying processes and discovering prospective treatment targets.
These illness models are essential tools for assessing the efficacy and safety of MSC therapy in preclinical trials, allowing researchers to adapt therapies to specific disease situations. Furthermore, disease modelling helps to identify patient populations that are most likely to benefit from MSC treatment, which guides clinical trial design and patient selection.
As the scientific knowledge of disease pathophysiology evolves, disease modelling enables the development and optimisation of MSC-based therapeutics, promoting market innovation and growth while ultimately improving patient outcomes.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 3.4 Billion |
| Projected Market Size in 2033 | USD 7.7 Billion |
| Market Size in 2023 | USD 3.2 Billion |
| CAGR Growth Rate | 12.7% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type, Source of Isolation, Application and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Mesenchymal Stem Cell Therapy Market: Regional Analysis
By region, Mesenchymal Stem Cell Therapy market is segmented into North America, Europe, Asia-Pacific, Latin America, the Middle East & Africa. North America dominated the global Mesenchymal Stem Cell Therapy market in 2023 with a market share of 40.7% and is expected to keep its dominance during the forecast period 2024-2033.
North America drives the mesenchymal stem cell treatment market with its strong infrastructure, cutting-edge research facilities, and considerable expenditures in biomedical technology. With a high frequency of chronic illnesses and an ageing population, there is an increasing need for regenerative therapies.
Furthermore, strict regulatory frameworks assure quality control and safety standards, increasing customer trust in the efficacy of stem cell treatments. Academic institutions, pharmaceutical corporations, and biotechnology enterprises work closely together to create a vibrant laboratory and research environment.
Furthermore, the area has a robust network of physicians and medical professionals who are eager to implement novel therapies, which drives market growth. This confluence between scientific competence, regulatory backing, and healthcare infrastructure puts North America as a key force in progressing mesenchymal stem cell treatment, altering the trajectory of regenerative medicine on a global scale.
Mesenchymal Stem Cell Therapy Market: Recent Developments
- In November 2023, Mesoblast collaborated with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a clinical study investigating its Ryoncil (remestemcel-L) in steroid-refractory acute graft versus host disease (SR-aGvHD).
- In October 2023, TiGenix NV declared that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the therapy of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn’s disease. This is the first allogeneic stem cell treatment to get central marketing authorization (MA) approval in Europe.
- In May 2023, Stemmatters and Pluristyx established a cooperation to boost the advancement of induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell banks.
List of the prominent players in the Mesenchymal Stem Cell Therapy Market:
- Mesoblast Limited
- TiGenix
- Osiris Therapeutics
- Celgene Corporation
- Vericel Corporation
- Athersys Inc.
- NuVasive Inc.
- Orthofix Medical Inc.
- Regeneus Ltd.
- Pluristem Therapeutics Inc.
- ReNeuron Group plc
- Anterogen Co. Ltd.
- Pharmicell Co. Ltd.
- Cytori Therapeutics Inc.
- Mesoblast Limited
- Stempeutics Research Pvt. Ltd.
- Mesenchymal Stem Cells of Georgia LLC
- Capricor Therapeutics
- Celltex Therapeutics Corporation
- Cells for Cells S.A.
- Others
These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.
The Mesenchymal Stem Cell Therapy Market is segmented as follows:
By Type
- Autologous
- Allogeneic
By Source of Isolation
- Bone Marrow
- Cord Blood
- Peripheral Blood
- Fallopian Tube
- Fetal Liver
- Lung
- Adipose Tissues
By Application
- Disease Modelling
- Drug Development & Discovery
- Stem Cell Banking
- Tissue Engineering
- Toxicology Studies
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Mesenchymal Stem Cell Therapy Market, (2024 – 2033) (USD Billion)
- 2.2 Global Mesenchymal Stem Cell Therapy Market: snapshot
- Chapter 3. Global Mesenchymal Stem Cell Therapy Market – Industry Analysis
- 3.1 Mesenchymal Stem Cell Therapy Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Increase in prevalence of chronic diseases
- 3.2.2 Growing prominence of regenerative medicine
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Source of Isolation
- 3.7.3 Market Attractiveness Analysis By Application
- Chapter 4. Global Mesenchymal Stem Cell Therapy Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Mesenchymal Stem Cell Therapy Market: company market share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Mesenchymal Stem Cell Therapy Market – Type Analysis
- 5.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Type
- 5.1.1 Global Mesenchymal Stem Cell Therapy Market Share, By Type, 2023 and 2033
- 5.2 Autologous
- 5.2.1 Global Mesenchymal Stem Cell Therapy Market by Autologous, 2024 – 2033 (USD Billion)
- 5.3 Allogeneic
- 5.3.1 Global Mesenchymal Stem Cell Therapy Market by Allogeneic, 2024 – 2033 (USD Billion)
- 5.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Type
- Chapter 6. Global Mesenchymal Stem Cell Therapy Market – Source of Isolation Analysis
- 6.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Source of Isolation
- 6.1.1 Global Mesenchymal Stem Cell Therapy Market Share, By Source of Isolation, 2023 and 2033
- 6.2 Bone Marrow
- 6.2.1 Global Mesenchymal Stem Cell Therapy Market by Bone Marrow, 2024 – 2033 (USD Billion)
- 6.3 Cord Blood
- 6.3.1 Global Mesenchymal Stem Cell Therapy Market by Cord Blood, 2024 – 2033 (USD Billion)
- 6.4 Peripheral Blood
- 6.4.1 Global Mesenchymal Stem Cell Therapy Market by Peripheral Blood, 2024 – 2033 (USD Billion)
- 6.5 Fallopian Tube
- 6.5.1 Global Mesenchymal Stem Cell Therapy Market by Fallopian Tube, 2024 – 2033 (USD Billion)
- 6.6 Fetal Liver
- 6.6.1 Global Mesenchymal Stem Cell Therapy Market by Fetal Liver, 2024 – 2033 (USD Billion)
- 6.7 Lung
- 6.7.1 Global Mesenchymal Stem Cell Therapy Market by Lung, 2024 – 2033 (USD Billion)
- 6.8 Adipose Tissues
- 6.8.1 Global Mesenchymal Stem Cell Therapy Market by Adipose Tissues, 2024 – 2033 (USD Billion)
- 6.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Source of Isolation
- Chapter 7. Global Mesenchymal Stem Cell Therapy Market – Application Analysis
- 7.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Application
- 7.1.1 Global Mesenchymal Stem Cell Therapy Market Share, By Application, 2023 and 2033
- 7.2 Disease Modelling
- 7.2.1 Global Mesenchymal Stem Cell Therapy Market by Disease Modelling, 2024 – 2033 (USD Billion)
- 7.3 Drug Development & Discovery
- 7.3.1 Global Mesenchymal Stem Cell Therapy Market by Drug Development & Discovery, 2024 – 2033 (USD Billion)
- 7.4 Stem Cell Banking
- 7.4.1 Global Mesenchymal Stem Cell Therapy Market by Stem Cell Banking, 2024 – 2033 (USD Billion)
- 7.5 Tissue Engineering
- 7.5.1 Global Mesenchymal Stem Cell Therapy Market by Tissue Engineering, 2024 – 2033 (USD Billion)
- 7.6 Toxicology Studies
- 7.6.1 Global Mesenchymal Stem Cell Therapy Market by Toxicology Studies, 2024 – 2033 (USD Billion)
- 7.7 Others
- 7.7.1 Global Mesenchymal Stem Cell Therapy Market by Others, 2024 – 2033 (USD Billion)
- 7.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Application
- Chapter 8. Mesenchymal Stem Cell Therapy Market – Regional Analysis
- 8.1 Global Mesenchymal Stem Cell Therapy Market Regional Overview
- 8.2 Global Mesenchymal Stem Cell Therapy Market Share, by Region, 2023 & 2033 (USD Billion)
- 8.3. North America
- 8.3.1 North America Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.3.1.1 North America Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
- 8.3.1 North America Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.4 North America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
- 8.4.1 North America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
- 8.5 North America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
- 8.5.1 North America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
- 8.6 North America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
- 8.6.1 North America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
- 8.7. Europe
- 8.7.1 Europe Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.7.1.1 Europe Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
- 8.7.1 Europe Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.8 Europe Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
- 8.8.1 Europe Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
- 8.9 Europe Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
- 8.9.1 Europe Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
- 8.10 Europe Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
- 8.10.1 Europe Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
- 8.11. Asia Pacific
- 8.11.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.11.1.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
- 8.11.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.12 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
- 8.12.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
- 8.13 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
- 8.13.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
- 8.14 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
- 8.14.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
- 8.15. Latin America
- 8.15.1 Latin America Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.15.1.1 Latin America Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
- 8.15.1 Latin America Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.16 Latin America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
- 8.16.1 Latin America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
- 8.17 Latin America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
- 8.17.1 Latin America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
- 8.18 Latin America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
- 8.18.1 Latin America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
- 8.19. The Middle-East and Africa
- 8.19.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.19.1.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
- 8.19.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
- 8.20 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
- 8.20.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
- 8.21 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
- 8.21.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
- 8.22 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
- 8.22.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 Mesoblast Limited
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 TiGenix
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Osiris Therapeutics
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Celgene Corporation
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Vericel Corporation
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Athersys Inc.
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 NuVasive Inc.
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Orthofix Medical Inc.
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Regeneus Ltd.
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Pluristem Therapeutics Inc.
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 ReNeuron Group plc
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 Anterogen Co. Ltd.
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Pharmicell Co. Ltd.
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 Cytori Therapeutics Inc.
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.15 Mesoblast Limited
- 9.15.1 Overview
- 9.15.2 Financials
- 9.15.3 Product Portfolio
- 9.15.4 Business Strategy
- 9.15.5 Recent Developments
- 9.16 Stempeutics Research Pvt. Ltd.
- 9.16.1 Overview
- 9.16.2 Financials
- 9.16.3 Product Portfolio
- 9.16.4 Business Strategy
- 9.16.5 Recent Developments
- 9.17 Mesenchymal Stem Cells of Georgia LLC
- 9.17.1 Overview
- 9.17.2 Financials
- 9.17.3 Product Portfolio
- 9.17.4 Business Strategy
- 9.17.5 Recent Developments
- 9.18 Capricor Therapeutics
- 9.18.1 Overview
- 9.18.2 Financials
- 9.18.3 Product Portfolio
- 9.18.4 Business Strategy
- 9.18.5 Recent Developments
- 9.19 Celltex Therapeutics Corporation
- 9.19.1 Overview
- 9.19.2 Financials
- 9.19.3 Product Portfolio
- 9.19.4 Business Strategy
- 9.19.5 Recent Developments
- 9.20 Cells for Cells S.A.
- 9.20.1 Overview
- 9.20.2 Financials
- 9.20.3 Product Portfolio
- 9.20.4 Business Strategy
- 9.20.5 Recent Developments
- 9.21 Others.
- 9.21.1 Overview
- 9.21.2 Financials
- 9.21.3 Product Portfolio
- 9.21.4 Business Strategy
- 9.21.5 Recent Developments
- 9.1 Mesoblast Limited
List Of Figures
Figures No 1 to 31
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Mesoblast Limited
- TiGenix
- Osiris Therapeutics
- Celgene Corporation
- Vericel Corporation
- Athersys Inc.
- NuVasive Inc.
- Orthofix Medical Inc.
- Regeneus Ltd.
- Pluristem Therapeutics Inc.
- ReNeuron Group plc
- Anterogen Co. Ltd.
- Pharmicell Co. Ltd.
- Cytori Therapeutics Inc.
- Mesoblast Limited
- Stempeutics Research Pvt. Ltd.
- Mesenchymal Stem Cells of Georgia LLC
- Capricor Therapeutics
- Celltex Therapeutics Corporation
- Cells for Cells S.A.
- Others
FAQs
The major driver for the Mesenchymal Stem Cell Therapy market is increase in prevalence of chronic diseases and growing prominence of regenerative medicine.
The “Disease Modelling” had the largest share in the global market for Mesenchymal Stem Cell Therapy.
The “Autologous” category dominated the market in 2023.
The key players in the market are Mesoblast Limited, TiGenix, Osiris Therapeutics , Celgene Corporation , Vericel Corporation, Athersys Inc., NuVasive Inc., Orthofix Medical Inc., Regeneus Ltd., Pluristem Therapeutics Inc., ReNeuron Group plc, Anterogen Co. Ltd., Pharmicell Co. Ltd., Cytori Therapeutics Inc., Mesoblast Limited, Stempeutics Research Pvt. Ltd. , Mesenchymal Stem Cells of Georgia LLC, Capricor Therapeutics, Celltex Therapeutics Corporation, Cells for Cells S.A., Others.
“North America” had the largest share in the Mesenchymal Stem Cell Therapy Market.
The global market is projected to grow at a CAGR of 12.7% during the forecast period, 2024-2033.
The Mesenchymal Stem Cell Therapy Market size was valued at USD 3.4 Billion in 2024.